2003, Drug Development and Small Molecule

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2003

Drug Development

Small Molecule

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

The Pharma Data

DECEMBER 15, 2020

Approval demonstrates our ability to execute upon the entirety of the drug development and registration process. We believe this small molecule platform has the potential beyond actinic keratosis and are leveraging the platform to develop therapies for other oncology indications.”. Founded in 2003, Athenex, Inc.

FDA Approval

FDA Approval Treatment FDA Therapies

Enlisting Monoclonal Antibodies in the Fight Against COVID-19

NIH Director's Blog: Drug Development

MAY 21, 2020

One advantage of this class of therapeutics is that the timelines for their development, testing, and approval are typically shorter than those for drugs made of chemical compounds, called small molecules.

Virus

Virus Vaccine Laboratories Small Molecule

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Drug Discovery Digest

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

Enlisting Monoclonal Antibodies in the Fight Against COVID-19

Webinars

Stay Connected